Secnidazole + Fluconazole + Azithromycin KitThird Party Manufacturing in India

The Secnidazole + Fluconazole + Azithromycin Kit combines three synergistic mechanisms to treat polymicrobial urogenital infections. Secnidazole, a second-generation nitroimidazole, enters microbial cells and undergoes intracellular reduction. The reduced metabolite causes DNA helix destabilisation and strand breakage, providing potent activity against Trichomonas vaginalis, Gardnerella vaginalis, and other anaerobic pathogens. Secnidazole offers the advantage of single-dose therapy due to its long half-life of approximately 17-29 hours. Fluconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol biosynthesis in the Candida cell membrane. This leads to membrane permeabilisation and fungistatic activity against susceptible Candida species. Azithromycin binds to the 50S ribosomal subunit of bacteria, blocking the translocation step in protein synthesis. It provides coverage against Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. The combination ensures comprehensive treatment of mixed infections in a single kit regimen, reducing compliance failure and the risk of incomplete cure.

Therapeutic Uses

The Secnidazole + Fluconazole + Azithromycin Kit is prescribed for the treatment of:

• Mixed Vaginal Infections: Single-course therapy for infections involving Trichomonas vaginalis, Candida albicans, and bacterial vaginosis pathogens.
• Sexually Transmitted Infections: Empiric coverage of common STI pathogens including Chlamydia, gonorrhoea, and trichomoniasis.
• Bacterial Vaginosis with Candidal Co-infection: Treatment of mixed vaginal flora disturbances where both bacterial and fungal components are present.
• Urethritis and Cervicitis: Management of non-gonococcal urethritis and cervicitis with mixed aetiology.

Why Manufacturers Choose This Kit

The Secnidazole-based combination kit offers a competitive alternative to the Ornidazole variant due to Secnidazole's longer half-life, which enables once-daily or single-dose administration. This dosing convenience is highly valued in STI treatment where patient compliance is often suboptimal. The Indian pharmaceutical market has seen increasing demand for combination kits that simplify treatment regimens for primary care providers. For third party manufacturers, this kit leverages established supply chains for all three APIs and uses standard tablet compression technology. The kit packaging format — including Secnidazole 750mg tablets, Fluconazole 150mg, and Azithromycin 1gm — creates a differentiated product with strong brand recall potential for PCD franchise partners.

This makes this kit one of the most sought-after products for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.